Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 1.00 |
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30925315 | 1.00 | JAK2 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2640611 | 0.92 | JAK2 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2635152 | 0.92 | PTK2 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2634517 | 0.91 | JAK2 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL3764388 | 0.91 | JAK2 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2640369 | 0.90 | JAK3 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2634845 | 0.90 | JAK3 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL2634395 | 0.90 | JAK3 (1.00) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL12973847 | 0.90 | JAK2 (0.81) | JAK2JAK3PTK2JAK1ABCB1 | |
| SCHEMBL22511746 | 0.90 | JAK3 (0.81) | JAK2JAK3PTK2JAK1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12559553-B2 | IL-31 modulators for treating FXR-induced pruritus | GILEAD SCIENCES, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20250025542-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE | THE UNIVERSITY OF CHICAGO (US) | 2025-01-23 | — | — | US | claimed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| CN-118715226-A | Compounds and uses thereof | 上海岸阔医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4355422-A1 | IL-31 MODULATORS FOR TREATING FXR-INDUCED PRURITIS | GILEAD SCIENCES, INC. (US) | 2024-04-24 | — | — | EP | claimed |
| CN-111154711-B | Application of JAK2 inhibitor in induced differentiation of islet beta cells | 杭州瑞普晨创科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | claimed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | claimed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | claimed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | claimed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK2 1/4885JAK3 19/4885PTK2 703/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | JAK2 3633/4885JAK3 3729/4885PTK2 1851/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK2 1/4885JAK3 91/4885PTK2 926/4885 |
| US-12559553-B2 | IL-31 modulators for treating FXR-induced pruritus | NR1H4, NR1H3, NR1H2 | JAK2 167/4885JAK3 43/4885PTK2 996/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK2 31/4885JAK3 175/4885PTK2 1114/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | JAK2 1497/4885JAK3 4037/4885PTK2 3448/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | JAK2 3466/4885JAK3 4798/4885PTK2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.